StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Alpine Immune Sciences by Year

Alpine Immune Sciences — Cash and cash equivalents ($M) ($M)

Vertex Pharmaceuticals Alpine Immune Sciences: $43.9M in FY2023, up 228.3% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023
43.9
Period ended Dec 31, 2023
Change on a year earlier
+228.3%
13.4 in FY2022
History
6 years
Since FY2018
Sources
6
Documents cited below

Where the FY2023 figure comes from

Source: SEC Filing ↗

Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAlpine Immune Sciences — Cash and cash equivalents ($M) ($M)Year on yearSource
FY2023Dec 31, 202343.9+228.3%SEC Filing ↗
FY2022Dec 31, 202213.4-80.3%SEC Filing ↗
FY2021Dec 31, 202167.9+94.3%SEC Filing ↗
FY2020Dec 31, 202035.0+116.9%SEC Filing ↗
FY2019Dec 31, 201916.1+50.5%SEC Filing ↗
FY2018Dec 31, 201810.7–SEC Filing ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences ($M), annual FY2018–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-cash

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.